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A B S T R A C T
Psychosis is associated with low-grade inflammation as measured by high-sensitivity C-reactive protein (hs-
CRP), a risk factor for cardiovascular events and mortality in the general population. We investigated the re-
lationship between hs-CRP and anthropometric and metabolic changes in first-episode psychosis (FEP) during
the first treatment year. We recruited 95 FEP patients and 62 controls, and measured longitudinal changes in hs-
CRP, weight, waist circumference, insulin resistance, and lipids. We used linear mixed models to analyze the
longitudinal relationship between hs-CRP and clinical, anthropometric and metabolic measures. At baseline,
patients with FEP had higher levels of insulin resistance, total and low-density lipoprotein cholesterol, apoli-
poprotein B, and triglycerides. Baseline weight, waist circumference, hs-CRP, fasting glucose, and high-density
lipoprotein cholesterol were similar between patients and controls. Marked increases in anthropometric mea-
sures and hs-CRP were observed in FEP during the 12-month follow-up. However, glucose and lipid parameters
did not change significantly. In the mixed models, waist circumference and female sex were significant pre-
dictors of hs-CRP levels in FEP. Prevention of the early development of abdominal obesity in FEP is crucial, as
abdominal obesity is accompanied by chronic low-grade inflammation, which increases further the cardiovas-
cular risk in this vulnerable population.
1. Introduction
There is evidence of systemic low-grade inflammation, as measured
by the inflammatory marker C-reactive protein (CRP), in severe mental
disorders, including schizophrenia (Fernandes et al., 2016), bipolar
disorder (Dargél et al., 2015), and major depression (Howren et al.,
2009; Wium-Andersen et al., 2013). CRP is a pro-inflammatory protein
produced by the liver, and adipocytes may also produce CRP in obese
individuals (Anty et al., 2006). The production of CRP is stimulated by
the cytokine interleukin 6 (Castell et al., 1990), which is also increased
in psychiatric disorders, especially during acute episodes
(Goldsmith et al., 2016). CRP has a role in the innate immune system
where it activates the complement cascade by binding to the surface of
microbes or to compounds released from damaged cells (Pepys and
Hirschfield, 2003). High-sensitivity CRP (hs-CRP) assays can be used as
a marker of chronic low-grade inflammation. CRP is strongly correlated
with body mass index (BMI; r=0.36, 95% CI=0.30 to 0.42) and waist
circumference (r=0.40, 95% CI=0.31 to 0.48) in the general popu-
lation (Choi et al., 2013). An unhealthy lifestyle can also contribute to
an increase in low-grade inflammation; pro-inflammatory activation is
associated with a lack of exercise (Hamer et al., 2012), irregular
sleeping habits (Wright et al., 2015), and cigarette smoking (Gonçalves
et al., 2011; Tibuakuu et al., 2017). Low-grade inflammation predicts
insulin resistance (Reilly and Saltiel, 2017), an increased risk of
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cardiovascular diseases (Emerging Risk Factors Collaboration et al.,
2010), type 2 diabetes, and cancer (Allin and Nordestgaard, 2011; Calle
and Fernandez, 2012). Specifically, CRP is a risk marker for cardio-
vascular events in the general population, as well as for vascular,
cancer, and lung disease mortality (Emerging Risk Factors
Collaboration et al., 2010). CRP has been suggested as a useful bio-
chemical risk marker of atherosclerotic cardiovascular disease
(Akintoye et al., 2017).
Low-grade inflammation is observed in various mental disorders
(Pinto et al., 2017). Accumulating risk factors predispose people with
psychiatric disorders to a low-grade inflammatory response. For ex-
ample, abdominal obesity is prevalent in schizophrenia, bipolar dis-
order, and major depression (de Wit et al., 2010; Manu et al., 2015;
McElroy and Keck, 2012; Saarni et al., 2009). Additionally, people af-
fected by severe mental illness are, on average, physically less active
(Stubbs et al., 2016) and smoke more (Dickerson et al., 2017) than the
general population. Antipsychotic medication has a strong propensity
to cause weight gain and disturb glucose and lipid metabolism (Bak
et al., 2014; Newcomer, 2005; Tek et al., 2016). Weight gain in first-
episode psychosis (FEP) is usually rapid during the first weeks and
months of antipsychotic treatment (Keinänen et al., 2015; Perez-Iglesias
et al., 2014; Tek et al., 2016). Fat accumulation associated with anti-
psychotic use especially concentrates in the abdomen, resulting in the
metabolically most unfavorable form of obesity (Gonçalves et al.,
2015). Altogether, these findings suggest a potential role for hs-CRP as
an early marker of a process leading to a robust increase in the meta-
bolic and cardiovascular morbidity, as well as mortality, in severe
mental illness. This was recently supported by a register-based study
where hs-CRP was associated with increased all-cause mortality in
people with schizophrenia during a 12-year study period (Horsdal et al.,
2017).
The aim of this study was to evaluate how low-grade inflammation,
measured by hs-CRP, develops during the first year in FEP. In addition,
we investigated longitudinal changes in BMI, waist circumference,
glucose, insulin, and lipids. We evaluated the longitudinal effects of risk
factors—such as weight gain, abdominal fat, insulin resistance, medi-
cation, and smoking—in the development of inflammation. We hy-
pothesized that an hs-CRP rise would be connected to increasing waist
circumference and weight, reflecting the pro-inflammatory activation
caused by visceral fat accumulation. Furthermore, we hypothesized that
the effect of antipsychotics on hs-CRP would be due to increased waist
circumference.
2. Methods
2.1. Clinical study protocol and assessment
The Helsinki Early Psychosis Study recruited FEP patients (aged 18
to 40 years old) attaining their first treatment for psychosis in the
catchment area of the Helsinki University Hospital and Helsinki
Psychiatric Services in the time period from December 2010 to June
2016. The inclusion criteria for the study were receiving a score of at
least 4 for unusual thought content or hallucinations on the Brief
Psychiatric Rating Scale - Expanded (BPRS-E) (Ventura et al., 1993) and
fluency in the Finnish language. The diagnoses of psychotic disorders
according to the DSM-IV criteria were later verified using the Struc-
tured Diagnostic Interview for DSM-IV, Research version (First et al.,
2002) as well as a review of all medical records. Substance-induced
psychotic disorders and psychotic disorders due to a general medical
condition were excluded. Patients with FEP were assessed three times.
Baseline assessment was conducted as soon as the patient had entered
treatment and was able to give informed consent according to the
treating personnel. Follow-ups were conducted at two and 12 months.
Data were gathered on sociodemographic factors, functioning, medi-
cation, physical illness, substance use, physical activity, diet, and
smoking; the interviewer measured weight, height, blood pressure, and
waist circumference. A full description of the assessment methods and
variables is given in the section Supplementary Methods.
Controls—matched by age, sex, and region of residence—were
identified from the Population Register Center and assessed at baseline
and 12 months with the same protocol as the patients. The exclusion
criteria for the controls were a lifetime history of psychotic disorder;
chronic neurological, endocrinological, or cardiovascular diseases; and
any condition that prevents magnetic resonance imaging.
The study was carried out in accordance with the International Code
of Medical Ethics of the World Medical Association (the Declaration of
Helsinki). The study protocol was approved by the Ethics Committee of
the Hospital District of Helsinki and Uusimaa and by the institutional
review boards of the National Institute for Health and Welfare (THL),
Helsinki, Finland, and the University of Helsinki. All participants gave a
written informed consent.
2.2. Laboratory analytical methods
A fasting blood sample was collected at some time between 8 and 10
am. Serum and plasma samples were immediately aliquoted and stored
at− 80 °C. Serum total cholesterol, high-density lipoprotein (HDL)
cholesterol, triglycerides, hs-CRP, insulin, apolipoprotein A-I (ApoA-I)
and apolipoprotein B (ApoB), and plasma glucose were measured on an
Abbott Architect ci8200 analyzer (Abbott Laboratories, Abbott Park, IL,
USA) in the laboratory of the Genomics and Biomarkers Unit at the
National Institute for Health and Welfare. The laboratory has been
accredited by the Finnish Accreditation Service and it fulfills the re-
quirements of the standards SFS-EN ISO/IEC 17025:2005. The scope of
accreditation covers all analyses. The following methods were used:
enzymatic assays for measuring total cholesterol, triglycerides, and
glucose; the homogenous method for direct measurement of HDL cho-
lesterol; ultrasensitive immunoturbidimetric assays for ApoA-I, ApoB,
and hs-CRP; and a chemiluminescent microparticle immunoassay
(CMIA) for insulin. Low-density lipoprotein (LDL) cholesterol was cal-
culated by the Friedewald formula. The mean inter-assay coefficients of
variation (CVs) for total cholesterol, HDL cholesterol, triglycerides, hs-
CRP, insulin, ApoA-I, ApoB, and glucose were 1.0%, 1.1%, 0.8%, 2.8%,
1.9%, 1.2%, 1.7%, and 1.1%, respectively.
2.3. Statistical analysis of clinical data
Because most of the variables were not normally distributed, we
calculated descriptive statistics for sociodemographic and clinical
measures using tests for non-normally distributed variables. Thus, we
used Pearson's χ2 tests (Fisher's exact test) or the Mann-Whitney U-test
to test significance in between-group comparisons, and we used
Spearman's rank order correlations to test correlations. Friedman's
ANOVA was used to test differences between baseline, and two-month
and 12-month assessments for patients who had measurements avail-
able at all time points. Cochran's Q test was used for categorical vari-
ables. For descriptive purposes, we present all p-values significant at
the< 0.05 level. The p-values for post-hoc pairwise tests conducted
after Friedman´s ANOVA and Cochran´s Q test were Bonferroni cor-
rected.
The statistical comparisons were run on SPSS version 24. We per-
formed mixed effects models using SAS's PROC MIXED to analyze which
variables associated with longitudinal changes in hs-CRP in patients.
Based on evaluation of model residuals, we applied a logarithm trans-
formation to hs-CRP to reduce the skewness of its distribution (referred
to as logCRP). The selection of model variables was based on the
Bayesian information criterion (BIC) (Schwarz, 1978). As there were
marked changes in waist circumference and weight over the study
period, we analyzed these variables as time dependent. Baseline
smoking status was used in the analysis because few patients either
started or quitted smoking during the study period, and the amount of
missing data on smoking was smallest at baseline. Other variables
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considered as potentially associated with hs-CRP were insulin, the
homeostatic model assessment (HOMA) index (a measure of insulin
resistance), clozapine and olanzapine use, and cannabis use.
3. Results
3.1. Descriptors of the cohort at baseline
Altogether 95 patients and 62 controls took part in the study at
baseline. Baseline serum samples were available for 84 patients and 51
controls. Serum samples at the two-month follow-up were available for
67 patients (80% of the initial sample) and at the 12-month follow-up
for 52 patients (62% of the initial sample). Plasma samples for glucose
measurement were available for one additional patient in each mea-
surement. The Supplementary Table 1 shows the data available at all
three assessments. Patients had a median (Mdn) of 22 days (inter-
quartile range [IQR]: 10–49 days) of antipsychotic use at baseline.
The baseline demographic and clinical characteristics of patients
and controls are shown in Table 1. At baseline, there were no significant
differences between patients and controls in the lifestyle descriptors,
but patients were more often unemployed and living with their parents.
Schizophrenia was the most common diagnosis by the time of the
12-month follow-up (n=35, 37%) followed by schizophreniform dis-
order (n=22, 23%), psychotic disorder not otherwise specified
(n=19, 20%), bipolar disorder with psychotic features (n=8, 8%),
major depressive disorder with psychotic features (n=4, 4%), schi-
zoaffective disorder (n=3, 4%), brief psychotic disorder (n=3, 3%)
and delusional disorder (n=1, 1%).
Seven percent of patients (n=7) were not using antipsychotics at
the time of baseline assessment. Of patients using any antipsychotic
medication at baseline (n=88), 78 (89%) were prescribed anti-
psychotic monotherapy. Olanzapine was the most commonly prescribed
antipsychotic at baseline (n=35, 37%), followed by risperidone
(n=34, 36%), quetiapine (n=18, 19%) and other second-generation
antipsychotics (aripiprazole, sertindole, ziprasidone) (n=8, 8%). Four
percent of patients (n=4) were using first-generation antipsychotics at
baseline. Of patients, 60% (n=57) were hospitalized at baseline. Two
patients had insulin treatment for diabetes mellitus at baseline, one for
type 1 diabetes and another for type 2 diabetes.
At baseline, patients had higher insulin, insulin resistance (indicated
by their HOMA score), total cholesterol, LDL-cholesterol, apolipopro-
tein B, and triglyceride levels than controls, while hs-CRP at baseline
was similar (Table 2). In order to see whether antipsychotic use before
the baseline assessment had affected the metabolic parameters at
baseline, we divided patients into two groups according to the duration
of antipsychotic use before the baseline assessment, using the median
(22 days) as a cut-off. There were no statistically significant differences
between the two groups in baseline BMI, waist circumference, lipids,
glucose or hs-CRP.
3.2. Medication throughout the study period
Of those using olanzapine at baseline (n=35), 71% (20/28; 7
missing) were still using olanzapine at the two-month follow-up and
48% (10/21; 14 missing) at the 12-month follow-up.
The proportion of patients not using any antipsychotic at baseline,
Table 1
Baseline clinical and demographical characteristics of all first-episode psychosis (FEP) patients, FEP patients with 12-month follow-up data available, and controls.
FEP patients (n=95), n (%), FEP patients with 12-month follow-up data (CRP) Controls (n=62), n (%), p-valuea
or median (25%, 75%) available (N=52), n (%), or median (25%, 75%) or median (25%, 75%)
Age 24.9 (21.6, 29.4) 25.4 (22.6, 30.1) 24.0 (21.7, 28.7) 0.828
Male 65/95 (68%) 31/52 (60%) 40/62 (65%) 0.611
Living with parents 35/95 (37%) 18/52 (35%) 10/62 (16%) 0.005
No vocational or higher education 38/95 (40%) 15/52 (29%) 11/62 (18%) 0.003
Employed, military or student 73/95 (77%) 41/52 (79%) 59/62 (95%) 0.002
BMI 22.9 (21.1, 25.9) (n=94) 23.0 (20.9, 25.8) (n=83) 23.8 (21.8, 25.8) 0.356
Waist circumference (cm; total) 83.0 (78.0, 90.0) 82.5 (75.5, 89.0) 82.0 (77.0, 90.0) 0.519
Waist circumference (cm; men) 85.0 (81.0, 91.0) 84.0 (79.0, 89.0) 86.0 (78.0, 92.0) 0.443
Waist circumference (cm; women) 78.5 (69.8, 86.3) 79.0 (71.0, 84.5) 79.0 (72.8, 85.8) 0.584
Smoking 20/78 (26%) 9/47 (19%) 11/53 (21%) 0.518
No illicit substance use lifetimeb 40/74 (54%) 27/45 (60%) 26/51 (51%) 0.735
Active lifestylec 50/72 (69%) 33/44 (75%) 39/51 (77%) 0.391
Consumption of highly palatable foodsd 4.5 (0–9) (n=70) 4.5 (0–9) (n=44) 4 (1–9) (n=51) 0.932
Positive symptom scoree 6 (3, 9) 6.5 (3, 9) 0 (0, 0) 0.001
Negative symptom scoref 5 (3, 8) 5 (3, 8) 0 (0, 0) 0.001
AUDIT 5 (2, 12) (n=74) 4 (1, 12) (n=45) 6 (3, 9) 0.797
GAF 35 (31, 40) 35 (30, 40) 86 (77, 90) 0.001
Abbreviations: AUDIT, Alcohol use disorder identification test; BMI, Body mass index; GAF, Global assessment of functioning scale
a Mann-Whitney U test for continuous variables; chi-squared test for categorical variables.
b Substance use does not include alcohol, nicotine or caffeine.
c Easy exercise at least 4 h per week, self-reported.
d Sum score of the frequency of consumption of high-energy foods and drinks rich in fat and/or sugar (pizza, hamburgers, chocolate and sweets, cookies, pastries,
juices and beverages containing sugar).
e Sum score of BPRS-E items 10 (hallucinations), 11 (unusual thought content), 12 (bizarre behavior) and 15 (conceptual disorganization).
f Sum score of BPRS-E item 16 (blunted affect) and SANS-score (alogia, avolition-apathy, anhedonia-asociality).
Table 2
Baseline laboratory results of first-episode psychosis patients and controls.
Patients (n=84) Controls (n=51)
Variable Measure Median Median Ua p
hs-CRP mg/l 0.67 0.68 2111.5 0.890
Glucose mmol/l 4.11 (n=85) 4.06 2065.0 0.645
Insulin mU/l 8.85 7.40 1631.5 0.021
HOMA 1.60 1.31 1616.0 0.017
Cholesterol mmol/l 4.81 4.41 1695.0 0.042
HDL-C mmol/l 1.37 1.44 2513.5 0.092
LDL-C mmol/l 2.83 2.45 1612.5 0.016
Triglycerides mmol/l 1.11 0.83 1482.0 0.003
ApoA-I g/l 1.44 1.45 2471.5 0.135
ApoB g/l 0.84 0.73 1581.5 0.011
Abbreviations: ApoA-I, apolipoprotein A1; ApoB, apolipoprotein B; HDL-C,
high-density lipoprotein cholesterol; HOMA, homeostatic model assessment of
insulin resistance; hs-CRP, high sensitivity C-reactive protein; LDL-C, low-
density lipoprotein cholesterol.
a Mann-Whitney U test.
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or the two-month and 12-month follow-ups were 7% (7/95), and 8%
(6/77) and 22% (14/63), respectively. The Supplementary Table 2
shows the distribution of psychotropic medication use at each assess-
ment.
3.3. Metabolic measures and weight gain in patients at two and 12 months
As the dates for the two- and 12-month follow-up assessments were
agreed upon in cooperation with the patients, there were differences in
the actual time between assessments. The median intervals from base-
line to the two-month follow-up and from baseline to the 12-month
follow-up were 80 days (IQR 69–97 days) and 382 days (IQR 373–397
days), respectively. The median duration of antipsychotic use until the
12-month assessment was 402 days (IQR 374–453). Compared to
baseline, waist circumference and BMI had already significantly in-
creased at the time of the two-month follow-up, and continued to in-
crease until the 12-month measurement (Table 3). There were no sig-
nificant changes in glucose or insulin levels, blood lipids or
apolipoproteins between the baseline and the follow-up measurements.
The median 12-month weight gain among FEP patients was 9.6 kg
(IQR 1.4–13.6 kg), and the waist circumference increase was 6.0 cm
(IQR 2.0–13.0 cm). Compared to patients, controls had statistically
significantly less weight gain (Mdn 1.15 kg, IQR −1.14–2.29 kg,
U= 559.5, p<0.001) and increase in waist circumference (2.0 cm,
IQR −1.38–5.38 cm, U=658.0, p<0.001) by the 12-month follow-
up. By 12 months, 68% (40/59) of patients had clinically significant
weight gain (≥ 7% weight gain) as compared to baseline and 59% (35/
59) were overweight or obese. Fourteen percent of patients (8/59) had
lost weight by 12 months (range of weight loss: 0.2–3.5 kg). Of anti-
psychotics, olanzapine as baseline medication was associated with the
greatest 12-month weight increase. Patients using olanzapine at base-
line had a median 12-month weight increase of 11.8 kg (IQR
1.2–18.7 kg), while patients not using olanzapine at baseline had a
weight increase of 7.6 kg (IQR 1.5–12.5 kg, U= 498.0, p=0.056).
In comparison to FEP patients using antipsychotic medication at 12
months (n=42), those who were not using antipsychotic medication
(n=10) had less weight increase (respective median weight changes:
10.8 kg, IQR 4.0–14.4 kg compared to 5.6 kg, IQR− 1.7–10.0 kg;
U=201.5, p=0.043) and waist circumference increase (Mdn 1.0 cm,
IQR− 1.0–7.0 cm compared to Mdn 8.5 cm, IQR 4.0–15.3 cm;
U=160.5, p=0.011).
The proportion of patients who had elevated waist circumference
(> 94 cm for men,> 80 cm for women) at baseline was 27% (26/95),
and the proportion increased to 44% (34/77) by the two-month follow-
up and to 54% (32/59) by the 12-month follow-up (Cochran's Q test
χ2= 21.444, p<0.001) (Supplementary Table 3). Apart from waist
circumference increase, the prevalence of other metabolic syndrome
criteria did not increase significantly over time from baseline to 12-
month follow-up, although there was a trend for a higher prevalence of
metabolic syndrome at 12 months (Supplementary Table 3).
3.4. Gender differences in metabolic measures
Secondary analysis was done to explore gender differences. At
baseline, a statistically nonsignificant difference between the propor-
tion of women and men meeting the International Diabetes Federation
criteria for increased waist circumference (> 80 cm in women,> 94 cm
in men) was detected (40% and 22% respectively; χ2= 3.519,
p=0.061). Baseline BMI was similar between women and men (Mdn
22.4 kg/m2, IQR 20.7–25.5 kg/m2 compared to Mdn 22.9 kg/m2, IQR
21.2–26.1 kg/m2, respectively). At 12 months, no statistically sig-
nificant differences were detected in weight increase (12% and 14%
respective increase from baseline weight in women and men) nor in
waist circumference increase (7% and 12% increase from baseline).
There were no statistically significant differences in hs-CRP levels be-
tween women and men at any assessment point.
3.5. Hs-CRP increase and its predictors
The level of hs-CRP increased significantly in patients from the
baseline to the 12-month follow-up (Table 3). Patients who were not
using antipsychotics by the 12-month assessment had a trend for lower
12-month hs-CRP (Mdn 0.60, IQR 0.32–1.98mg/l) than those using
antipsychotics (Mdn 2.24mg/l, IQR 0.56–4.71mg/l; U=127.5,
p=0.055). Among controls, hs-CRP was 0.71mg/l at the 12-month
follow-up, which was statistically significantly lower than among pa-
tients (U= 565.5, p=0.014).
Since we wanted to focus the analysis on low-grade inflammation
and exclude patients who probably had an acute infection, we excluded
hs-CRP values higher than 10mg/l from the mixed effects models. The
Table 3














hs-CRP mg/l 0.67 0.33, 2.54 0.79 0.39, 1.92 1.73 0.49, 4.21 6.731 0.035; BL-2 m 1.000; BL-12m 0.066; 2m-
12m 0.087
Glucose mmol/l 4.11 (n=85) 3.75, 4.50 4.11 (n=68) 3.90, 4.49 4.23 (n=53) 3.95, 4.60 2.426 0.297







HOMA 1.60 1.14, 2.75 1.59 1.15, 2.62 1.62 1.10, 2.98 1.636 0.441
Cholesterol mmol/l 4.81 4.30, 5.37 4.96 4.31, 5.58 4.87 4.26, 5.36 0.354 0.838
HDL-C mmol/l 1.37 1.15, 1.56 1.33 1.16, 1.56 1.31 1.11, 1.63 0.149 0.928
LDL-C mmol/l 2.83 2.40, 3.38 3.02 2.45, 3.61 2.94 2.39, 3.39 0.966 0.617
Triglycerides mmol/l 1.11 0.75, 1.47 1.04 0.81, 1.47 1.03 0.66, 1.61 0.184 0.912
ApoA-I g/l 1.44 1.27, 1.55 1.42 1.26, 1.53 1.42 1.26, 1.56 0.667 0.717
ApoB g/l 0.84 0.73, 0.94 0.86 0.75, 1.00 0.86 0.72, 1.04 0.184 0.912
Waist circumference cm 83.0 (n=95) 78.0, 90.0 87.5 (n=77) 80.0, 99.5 89.0 (n=59) 82.0,
100.0
43.936 <0.001; BL-2m<0.001; BL-
12m<0.001; 2m-12m 0.249
BMI kg/m2 22.9 (n=94) 21.1, 25.9 24.2 (n=75) 21.5, 26.5 26.3 (n=59) 22.8, 30.5 44.545 <0.001; BL-2m 0.003; BL-12m<0.001;
2m-12m 0.003
a Friedman´s ANOVA.
b P-values for pairwise comparison are Bonferroni corrected; Abbreviations: ApoA-I, apolipoprotein A1; ApoB, apolipoprotein B; BL, baseline; 2m, 2-month follow-
up; 12m, 12-month follow-up; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; HOMA, homeostatic model assessment of insulin resistance; hs-
CRP, high sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol.
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respective number of patients having hs-CRP>10mg/l at baseline,
and two-month and 12-month measurements was three, and one and
five.
The best-fitting model for longitudinal changes in hs-CRP included a
random intercept for each patient and sex, time of assessment (days
from baseline measurement), waist circumference and antipsychotic
use at each assessment point, and baseline cigarette smoking. Waist
circumference (β=0.05048, standard error [SE]= 0.006646,
p<0.0001) and female sex (β=− 0.4721, SE=0.1882, p=0.0140)
were statistically significant predictors of higher logCRP. Other vari-
ables in this model did not reach statistical significance but based on
the BIC they contributed to the model fit. Other tested variables were
not significantly associated with logCRP and did not improve the model
fit, and therefore were not included in the final model. To further ex-
plore whether insulin resistance was a significant predictor of logCRP,
we included insulin resistance in the model (defined as HOMA above
the 75th percentile as in Keinänen et al. (2015), cut-off 2.75), but this
did not change results as waist circumference (p<0.0001) and female
sex (p=0.0149) were still the only significant predictors. Excluding a
patient with diabetes mellitus, who had CRP levels below 10mg/l,
slightly lowered the p-value of female sex (p=0.0216) but otherwise
did not change the results of the model.
Replacing waist circumference with BMI decreased the model's
goodness of fit slightly, but BMI was also a significant predictor of
logCRP (β=0.1163, SE= 0.01737, p<0.0001).
4. Discussion
We detected a remarkable increase in weight and waist cir-
cumference in this sample of FEP patients during the 12-month follow-
up. The changes in weight and waist circumference were predictors of
low-grade inflammation, as measured by hs-CRP. The observed increase
in abdominal obesity is rapid and of great clinical significance in young,
originally physically healthy adults.
We found no difference in hs-CRP at baseline between FEP patients
and controls. However, hs-CRP increased significantly during the 12-
month follow-up among FEP patients, and an increase in waist cir-
cumference, reflecting accumulating abdominal fat, was a strong pre-
dictor of hs-CRP increase. Waist circumference was a better predictor of
hs-CRP than BMI, which fits with findings from the general population
(Choi et al., 2013). In the general population, the accumulation of fat in
the liver and adipose tissue leads to an increase in hs-CRP, and in ad-
dition to the liver's production of CRP, adipose tissue is also a likely
source of CRP in obesity (Anty et al., 2006; Zimmermann et al., 2011).
The more than 2.5-fold increase in hs-CRP observed in our sample over
a one-year period is alarming, taking into account that elevated hs-CRP
is associated with an increased risk of cardiovascular disease
(Akintoye et al., 2017), and vascular and non-vascular mortality
(Emerging Risk Factors Collaboration et al., 2010). While only one
study has previously directly associated hs-CRP with prospective mor-
tality in people with severe mental disorders (Horsdal et al., 2017), the
robust increase in mortality of these disorders is well established
(Nordentoft et al., 2013; Walker et al., 2015). Female sex was also a
significant predictor of a higher hs-CRP level and women had a trend
for higher hs-CRP level at 12 months. This is in line with findings from
the general population that with increasing body fat and BMI, the CRP
increases more in women than in men (Choi et al., 2013; Khera et al.,
2009).
The FEP patients not using antipsychotics at the time of the 12-
month follow-up had a trend for lower hs-CRP compared to anti-
psychotic users, which is probably explained by the smaller increase in
waist circumference in non-medicated patients. On average, anti-
psychotics increase the expression of anti-inflammatory cytokines and
decrease the expression of pro-inflammatory cytokines (Fonseka et al.,
2016; Tourjman et al., 2013). However, the evidence is equivocal, as in
some studies the reverse—or no discernible effect—is detected during
antipsychotic use (Baumeister et al., 2016). Our results suggest that
weight gain and abdominal obesity are strong drivers of low-grade in-
flammation and override the potential anti-inflammatory effects that
antipsychotics may have.
We observed disturbances in glucose metabolism (i.e. insulin level
and insulin resistance) between patients and controls already at base-
line. However, there was no worsening of glucose homeostasis during
the follow-up. Recent meta-analyses show evidence of impaired glucose
tolerance and higher insulin resistance in antipsychotic-naïve FEP pa-
tients (Perry et al., 2016; Pillinger et al., 2017a). This could result from
an impairment of the hypothalamic-pituitary-adrenal axis function, as
FEP has been associated with hypercortisolemia and a blunted cortisol
awakening response (Borges et al., 2013). Antipsychotics, especially
olanzapine and clozapine, exacerbate elevated glucose levels and in-
crease insulin resistance (Henderson et al., 2006; Newcomer et al.,
2002). In our sample, only a minority of FEP patients were anti-
psychotic-naïve. It is thus possible that use of antipsychotics affected
the baseline differences in the present study. Lipid metabolism was
dysregulated at baseline in FEP as indicated by higher total cholesterol,
triglyceride, and LDL cholesterol and its structural component ApoB
levels. These observed differences in lipids could also reflect medication
effects. In particular, second-generation antipsychotic use is associated
with an increased risk of hyperlipidemia (Meyer and Koro, 2004). In-
vitro studies show that at first antipsychotics have a direct inhibitory
effect on enzymes controlling cholesterol biosynthesis (Canfran-Duque
et al., 2013; Kristiana et al., 2010), but a feedback mechanism then
increases the lipid synthesis in a matter of hours (Canfran-Duque et al.,
2013). It is of interest that, according to meta-analyses, drug-naïve FEP
patients may have lower total cholesterol, LDL and HDL cholesterol
levels and higher triglyceride levels than healthy controls (Misiak et al.,
2017; Pillinger et al., 2017b).
Previous literature has reported an association between high hs-CRP
levels and having schizophrenia (Fernandes et al., 2016; Inoshita et al.,
2016; Miller et al., 2014; Wang et al., 2017). Our findings are not in
total agreement with the results of the meta-analyses, as we did not
detect a baseline difference in hs-CRP but detected a significant in-
crease during the first treatment year, which was strongly related to an
increase in waist circumference. The largest meta-analysis
(Fernandes et al., 2016) including 26 studies found that CRP was in-
creased in both first-episode and chronic schizophrenia. The CRP levels
were associated with positive symptom severity and BMI but were not
affected by antipsychotic medication or progression of the disease from
first-episode to chronic. In a sub-group analysis where only studies with
BMI and age-adjusted controls were included, the CRP levels still re-
mained higher in schizophrenia (Fernandes et al., 2016). Mendelian
randomization studies analyzing the connection between genetic var-
iants affecting the CRP levels and schizophrenia risk have yielded
contradictory results (Hartwig et al., 2017; Inoshita et al., 2016; Prins
et al., 2016; Wium-Andersen et al., 2014). A recent study concluded
that genetically determined higher CRP levels were associated with a
decreased risk of schizophrenia (Hartwig et al., 2017). The authors
speculated that higher CRP might provide protection for early-life in-
fections and thus lower the risk of schizophrenia. We conclude that
future studies would benefit from using more homogenous groups in
terms of the type and duration of medication used as the controversial
findings might partially be explained by these factors.
The strengths of this study include a high-quality analysis of hs-CRP
in an internationally accredited laboratory. The results can be gen-
eralized to FEP patients during the first year of treatment. The controls
were randomly recruited from the general population and matched by
age, sex, and region of residence, reducing lifestyle-related socio-
demographic bias. Mixed model regression analysis allowed us to take
into account the individual differences in follow-up times, and allows
dependence between repeated observations. We used a prospective
follow-up of clinical information that was sampled utilizing many
sources, including medical records.
J. Keinänen et al. Psychiatry Research 270 (2018) 547–553
551
The limitations of our study include the rather small sample size at
the time of the 12-month assessment due to loss at follow-up (62% had
a blood sample available at 12-months). We did not detect any major
selection bias due to drop-out and do not expect that to affect our main
findings. Most patients were already using antipsychotic medication at
baseline. However, the short course of antipsychotic treatment did not
result in baseline differences in BMI and waist circumference, nor in hs-
CRP levels between patients and controls, and thus, did not limit our
analysis of the development of increased adiposity and low-grade in-
flammation. Another limitation is that physical activity was measured
with a single, self-report question that does not assess physical activity
according to the current recommendations (Bennie et al., 2017;
Vancampfort et al., 2016).
Hs-CRP was chosen as the main outcome measure because it can be
measured clinically as a marker of cardiovascular risk. However, our
results should not be interpreted as suggesting that all immunological
abnormalities related to psychotic disorders are caused by weight gain
or abdominal obesity. CRP is an acute phase protein produced by liver
and to some extent by adipose tissue, not a specific biomarker of im-
mune response. Many previous studies suggest that there are changes,
e.g., in T-cell activation, i.e. adaptive immunity, in recent onset psy-
chosis (Drexhage et al., 2011). Our results strengthen the view that
regular monitoring of the waist circumference should be an integral
part of follow-up of patients. In addition, the potential utility of hs-CRP
as a cardiovascular risk marker in patients with psychotic disorder
should be studied further.
In conclusion, we describe how a systemic low-grade inflammation
is tightly linked with abdominal fat accumulation in FEP during the first
year of treatment. Specifically, the low-grade inflammation as mea-
sured by hs-CRP was related to an increase in waist circumference and
female sex. Clinically, regular follow-up of waist circumference is im-
portant as a marker of metabolic and inflammatory changes and as a
robust marker of cardiovascular risk. Prevention of the early metabolic
changes in FEP is critical in reducing the risk of physical morbidity and
mortality in severe mental illness.
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